RLX Technology Inc. (RLX)
RLX trades on NYSE in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828365/000110465926047278/0001104659-26-047278-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RLX on NYSE |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | Cayman Islands |
| IPO year | 2021 |
| SEC CIK | 0001828365 |
| SEC industry code | Cigarettes |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $566.1M |
| Net income | $131.8M |
| Operating income | $47.0M |
| Net margin | 23.3% |
| Operating margin | 8.3% |
| Revenue growth | +50.3% |
| Cash | $767.5M |
| Total assets | $2.6B |
| P/E (computed) | 14.2× |
| P/S (computed) | 3.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-23 |
| Cash and burn | $767.5M cash; operating cash flow $39.5M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-03-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers Zhong Tian LLP, Beijing, China | PCAOB Form AP 2026-05-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $566.1M | $131.8M | $157.9M | $767.5M | $13.2M | $566.1M | 20-F 2026-04-23 |
| FY 2024 2024-12-31 | $376.6M | $75.6M | $117.0M | $766.3M | $5.5M | $376.6M | 20-F 2025-04-17 |
| FY 2023 2023-12-31 | $223.4M | $75.3M | $28.0M | $336.7M | No debt tags | $223.4M | 20-F 2024-04-19 |
| FY 2022 2022-12-31 | $773.2M | $209.0M | $70.6M | $183.9M | No debt tags | $773.2M | 20-F 2023-04-21 |
| FY 2021 2021-12-31 | $1.3B | $317.7M | $282.4M | $817.4M | No debt tags | $1.3B | 20-F 2022-04-29 |
| FY 2020 2020-12-31 | $585.4M | -$19.6M | $396.8M | $170.7M | No debt tags | $585.4M | 20-F 2021-04-23 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2021-01-22 |
| Latest annual report | 20-F | 2026-04-23 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-08-14 |
Source: SEC EDGAR submissions feed, 88 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.1% |
| 1 month | -8.8% |
| 3 months | -22.0% |
| Year to date | -33.0% |
| 1 year | -33.0% |
| From 52-week high | -39.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TRLV | Trulieve Cannabis Corp. Subordinate Voting Shares | $10.33 | -5.23% | $2.0B |
| RGC | Regencell Bioscience Holdings Limited | $4.72 | -4.45% | $2.3B |
| CRON | Cronos Group Inc. Common Share | $3.27 | -3.25% | $1.2B |
| DFTX | Definium Therapeutics Inc. Common Shares | $30.16 | -5.99% | $4.1B |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier